Complex medication for treatment of remote effects of poisoning by methemoglobin generators

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, in particular to medication for treatment of remote effects of poisoning by methemoglobin generators. Medication for treatment of remote effects of poisoning by methemoglobin generators, including dry extract of fruits and seeds of Schisandra (standardised by content of total amount of lignans not less than 2.5%) and cytoflavin, taken in definite ratio.

EFFECT: medication is efficient for treatment of remote effects of poisoning by methemoglobin generators.

6 tbl, 4 ex

 

The invention relates to medicine, in particular to the new integrated tools designed for the treatment of poisoning metgemoglobinoobrazovatelami (MGO).

Methemoglobinemia is one of the severe forms of toxic pathology blood when exposed to the ICO, leading to the development of secondary tissue hypoxia and require immediate therapy and correction of remote consequences [A.H. Hall, Kulig K.W., B.H. Rumack Drug-and chemical-induced methaemoglobinaemia: clinical features and management. - Med. Toxicol. - 1986. No. 1. - pp. 253-260].

Known drug Adaptivit", contain the seeds of schisandra, which can be used for the prevention of functional disorders and diseases, including exposure to MGO [RU No. 2114628]. However, in addition to antihypoxic action, taking into account the whole complex of pathological syndromes, developing as a result of poisoning MGO, preferably in the presence of therapeutic agents used in therapeutic purposes expressed antioxidant properties of a systemic nature (metabolic correction). This tool can be a drug cytoflavin metabolic corrector with a strong antioxidant effect produced on an industrial scale and is widely used as a metabolic drugs used in the treatment of chronic cerebral ischemia 1-2 is Tadei and asthenia [Kaptsov SV, Vakhrushev A., Pavlov J.V. Modern aspects of the use of antihypoxants in medicine critical States [New St. Petersburg medical Gazette, 2002. No. 2. - P.54-56, V.V. Afanasiev Cytoflavin in intensive care: a Manual for physicians. - SPb., 2005. - 36 S.].

The present invention is the creation of comprehensive tools, including the dry extract of the fruits and seeds of schisandra, standardized by the total content of Lignano not less than 2.5% (hereinafter lemongrass) and cytoflavin, with the aim of expanding Arsenal of tools designed to ensure long-term consequences of poisoning metgemoglobinoobrazovatelami (MGO) based on the available domestic raw materials.

The method of preparation of a dry extract: 100.0 g of dried fruits with seeds of schisandra chinensis is crushed to the size of particles passing through a sieve 1-2 mm Quantitatively transferred into percolator and spend removing extractives in the gradient of ethyl alcohol from 35 to 90% (mass-volume ratio). Maceration pause is 12 hours. The ratio of raw material and extractant without regard to moisture absorption is 1:50. The obtained extracts are combined and carried out the condensation under reduced pressure until a 1:10 ratio, and then sent to the plant for a dry extract by the method of drying in pseudovirions layer. The obtained extracts PL the species and seeds of schisandra store tightly sealed in dark glass bottles in a desiccator.

The obtained extract is standardized in accordance with the regulatory documents [of the State Pharmacopoeia of the Russian Federation, edition XII / "Publishing "Scientific center of expertise of medical application", 2008 - 704 S.: ill.] on physico-chemical methods in drug discovery research. The total content of active ingredients of a dry extract from the fruits and seeds of schisandra (lignans, in terms of schizandrin) was determined by the method of high performance liquid chromatography. The number Lignano was calculated by area under the curve of absorption main peak of schisandrin using GSO as a calibrator.

To examine the efficacy of preparing a composition containing cytoflavin and lemongrass, as follows: fixed combination - mixed dry extract of lemongrass with the substance of cytoflavin in the ratio 1:2-21; free combination - mixed dry extract of lemongrass with the substance of cytoflavin in different proportions. The mixture used for the preparation of solutions.

Pharmacological studies were carried out on nonlinear mice male rats and male lines Sprague-Dawley. Experimental animals were kept in standard vivarium conditions.

For the introduction of animals daily, was preparing a series of solutions of a combination of a dry extract from the fruits and seeds of schisandra by cytoflavin by dissolving the components of the combinations in the physiological solution of sodium chloride. Animals were injected exploring a combination of intragastric calculate the optimal volume of 0.1 ml per 10 g of body weight [Manual on experimental (preclinical) study of new pharmacological substances, M.: "Medicine", 2005, p.41-54]. All experiments used the solutions of combinations of lemongrass with cytoflavin prepared according to the above technology.

Examples demonstrating the effectiveness of the proposed integrated tools for treatment of the late effects of poisoning MGO in comparison with lemongrass below (examples 1-4).

Example 1. The integrated tools in acute hypoxic hypoxia. Acute hypoxic hypoxia, resulting from deficiency of oxygen deficiency in the air we breathe, reproduced in a model of acute hypobaric hypoxia (AGBG) [Lukyanova L.D., hazura CENTURIES, Pastushenkov " L.V. and other Methodological guidelines for experimental study of drugs proposed for clinical studies as antihypoxic agents. M the USSR Ministry of health, Approved by the Pharmacological Committee 11.04.1990. (minutes No. 7)]. Animals were placed in a hyperbaric chamber with ventilation and created a vacuum of air, corresponding to the height of 11000 m above sea level. The lifting speed was 50 m/sec. In animals already at an altitude of 3000 m was begun bespoke ustwo, appeared cyanosis, dyspnea, and tremor. Further developed convulsions, punctuated by periods of muscle weakness and adynamia. Death resulted from respiratory failure. Each experimental group consisted of 10 mice males. Study drugs and their combinations were injected daily for 14 days noninvasive probe intragastrically. Control animals were injected with water. On the 14th day of the experience, through 60 minutes after the last injection of the compounds under study, carried out the "rise" of animals in the chamber at the maximum "height" 11000 m above sea level. Registered life expectancy and survival of animals. The results obtained are presented in table 1. The analysis of the data found that both drugs showed antihypoxic activity in the conditions of AGBG. The maximum increase in survival rate and duration of life was provided by the introduction of a complex composed of cytoflavin and lemongrass. The survival rate was 90%, which exceeded the results obtained with the introduction of each drug separately. Thus, there was an additive synergism.

Example 2. The integrated tools in acute tissue (gistologicheskoe) hypoxia (GTG). Tissue (histotoxic) hypoxia, resulting from the impossibility of oxygen uptake by the tissues, was observed by blocking the cytochrome oxidases - the enzyme terminal segment of the respiratory chain nitroprusside recommended dose of 20 mg/kg [Lukyanova L.D., hazura CENTURIES, Pastushenkov " L.V. and other Methodological guidelines for experimental study of drugs proposed for clinical studies as antihypoxic agents. M the USSR Ministry of health, Approved by the Pharmacological Committee 11.04.1990. (minutes No. 7)]. Each experimental group consisted of 10 mice males. Study drugs and their combinations were injected daily for 14 days noninvasive probe intragastrically. On the 14th day experience through 30 minutes after the last injection of the studied compounds to animals intraperitoneally injected with a solution of sodium nitroprusside. Registered life expectancy and survival of animals. With the introduction of combinations of cytoflavin with lemongrass at doses of 10-100 mg/kg and 2.35-100.0 mg/kg, respectively, were identified potentiation of the effect, as it was possible to achieve survival of the animals, which were not observed in any of the other groups (table 2).

Example 3. The use of complex tools with lemongrass in acute himicheskoi hypoxia (OGG). Acute gemicescuu hypoxia, resulting from the reduction of oxygen capacity of hemoglobin, reproduced by poisoning the animals methemoglobin-educational sodium nitrite at a dose of 300 mg/kg [Lukyanova L.D.,hazura CENTURIES, The Pastushenkov " L.V. and other Methodological guidelines for experimental study of drugs proposed for clinical studies as antihypoxic agents. M the USSR Ministry of health. Approved Pharmacological Committee 11.04.1990. (minutes No. 7)]. Each experimental group consisted of 10 mice males. Study drugs were administered daily for 14 days noninvasive probe intragastrically. On the 14th day experience through 30 minutes after the last injection of the studied compounds to animals intraperitoneally injected with a solution of sodium nitrite at a dose of 300 mg/kg When modeling himicheskoi hypoxia in animals of the control group after 2-3 minutes after injection of sodium nitrite was shortness of breath, cyanosis of mucous membranes and skin, developed breathing of Cheyne-Stokes equations. In some animals was observed clinico-tonic convulsions.

In a model of acute himicheskoi hypoxia almost completely reproduced the results obtained under conditions of tissue hypoxia (table 3). Was revealed the survival of animals, which amounted to 10-20% in the absence of the background monotherapy, combined with the introduction of drugs in a wide range of doses and duration of life of the animals was significantly higher than the background monotherapy cytoflavin or lemon grass.

Thus was demonstrated the possibility of achieving additive is about synergy, and on models himicheskoi and tissue hypoxia and potentiation antihypoxic effect, the combined application of cytoflavin and lemongrass.

Example 4. The use of complex tools with sub-chronic poisoning aniline. Aniline hydrochloride (A) was administered in a dose of 500 mg/kg (dose, ½ LD50) intragastrically daily for 10 days. In the same period of time, daily, for 2 hours prior to receipt of aniline, intragastrically in the form of aqueous solutions were administered study drugs and their combinations. Each experimental group contained 10 rats-males. The obtained data are presented in tables 4-6. As follows from the data presented in tables, a pronounced effect was observed in the dose range for cytoflavin from 10 to 200 mg/kg and from 2.35 to 23.50 mg/kg for lemongrass. Their action is implemented at various stages of the pathogenesis of hypoxia caused by the toxic action of aniline. So, cytoflavin largely influenced indicators of tissue respiration, mainly increasing dehydrogenase activity, and contributed to the recovery of ferrous iron by increasing the pool of glutathione. The effect of lemongrass, largely manifested lipoic activity. Under the joint administration of these drugs and their effect in the administration of aniline increased, which was reflected in normalizati the estimated parameters, and optimal doses of ingredients was 2.35 mg/kg (lemongrass) and 50 mg/kg (cytoflavin) - the combination with a mixing ratio of 1:21.

Table 1
The results of comparative assessment of antihypoxic activity, we offer a comprehensive tool and its components in male mice in conditions AGBG
The experimental groupDose, mg/kgThe lifetime limit on the height, min (M±M)The growth time life, %Survival, %
Control-4.3±0,1-0
Cytoflavin1.010.9±0.1+1540
Cytoflavin10.011.4±0.4*+16510
Cytoflavin50.012.1±0.3*+181 20
Cytoflavin100.013.2±0.1*+20640
Cytoflavin200.014.8±0.1*+24440
Magnolia0.0512.8±0.5*+19740
Magnolia2.3516.9±0.8*+29380
Magnolia4.7017.6±0.6*+30980
Magnolia23.518.1±0.9*+32160
Magnolia47.015.7±0.6*+26560
Magnolia100.015.9±0.6*+265 60
Cytoflavin + lemongrass200+0.0516.2±0.5*+27650
Cytoflavin + lemongrass200+2.3516.4±0.9*+28150
Cytoflavin + lemongrass200+4.7014.0±0.7*+22540
Cytoflavin + lemongrass200+23.513.1±0.5*+20440
Cytoflavin + lemongrass200+47.012.7±0.8*+29540
Cytoflavin + lemongrass200+100.012.7±0.8*+29540
Cytoflavin + lemongrass100+0.0516.6±0.8*+28650
Cytoflavin + lemongrass 100+2.3517.3±0.8*+30260
Cytoflavin + lemongrass100+4.7017.8±0.4*+31360
Cytoflavin + lemongrass100+23.518.3±0.5*+32570
Cytoflavin + lemongrass100+47.018.9±0.7*+43970
Cytoflavin + lemongrass100+100.018.9±0.7*+43970
Cytoflavin + lemongrass50+0.0519.8±0.5*+36090
Cytoflavin + lemongrass50+2.3519.3±0.8*+34990
Cytoflavin + lemongrass50+4.7019.2±0.6*+346 90
Cytoflavin + lemongrass50+23.519.6±1.1*+35580
Cytoflavin + lemongrass50+47.016.3±1.0*+27950
Cytoflavin + lemongrass50+100.016.3±1.0*+27950
Cytoflavin + lemongrass10+2.3518.1±1.2*+32170
Cytoflavin + lemongrass10+4.7017.1±0.8*+29860
Cytoflavin + lemongrass10+23.515.6±0.7*+26250
Cytoflavin + lemongrass10+47.014.1±0.8*+22840
Cytoflavin + lemongrass 10+100.014.1±0.8*+22840
Cytoflavin + lemongrass1.0+2.3515.9±1.1*+26950
Cytoflavin + lemongrass1.0+4.7015.4±0.9*+25850
Cytoflavin + lemongrass1.0+23.516.0±0.7*+27260
Cytoflavin + lemongrass1.0+47.014.2±1.4*+23040
Cytoflavin + lemongrass1.0+100.014.1±1.4*+23040
Note: -*p≤0.05 compared to control

Table 2
The results of comparative assessment of antihypoxic activity proposed sets the SPE funds and its components in male mice in conditions GTG
The experimental groupDose, mg/kgLife duration in minutes (M±M)The growth time life, %Survival, %
Control-6.3±0.3-0
Cytoflavin100.026.0±0.7+3130
Magnolia4.7012.3±0.6+950
Cytoflavin + lemongrass200+0.0526.8±1.4+3250
Cytoflavin + lemongrass200+2.3529.0±1.2+36010
Cytoflavin + lemongrass200+4.7027.4±1.5+33510
Cytoflavin + Limoni the 200+23.528.9±0.9+3590
Cytoflavin + lemongrass200+47.025.0±2.3+2970
Cytoflavin + lemongrass200+100.025.0±2.3+2970
Cytoflavin + lemongrass100+0.0526.0±0.7+3120
Cytoflavin + lemongrass100+2.3529.0±1.0+3600
Cytoflavin + lemongrass100+4.7028.8±0.9+35710
Cytoflavin + lemongrass100+23.530.5±0.8*+38410
Cytoflavin + lemongrass100+47.033.8±1.2* +43620
Cytoflavin + lemongrass100+100.033.8±1.2*+43620
Cytoflavin + lemongrass50+0.0529.3±0.8*+36510
Cytoflavin + lemongrass50+2.3530.3±0.9*+38020
Cytoflavin + lemongrass50+2.3530.3±0.9*+38020
Cytoflavin + lemongrass50+4.7024.2±0.7+2840
Cytoflavin + lemongrass50+23.528.2±0.8*+34810
Cytoflavin + lemongrass50+47.029.2±1.5*+36310
Ziefle the Jn + lemongrass 50+100.029.1±1.5*+36310
Cytoflavin + lemongrass10+0.0528.0±0.8+3440
Cytoflavin + lemongrass10+2.3529.7±1.2+37110
Cytoflavin + lemongrass10+4.7031.8±1.0+40410
Cytoflavin + lemongrass10+23.530.1±1.7+37810
Cytoflavin + lemongrass10+47.032.1±1.1*+31810
Cytoflavin + lemongrass10+100.032.12±1.1*+31810
Notes. Differences in all experimental groups, a significant relative to the control. *- p which is 0.05 in relation to cytoflavin

Cytoflavin + lemongrass
Table 3
The results of comparative assessment of antihypoxic activity, we offer a comprehensive tool and its components in male mice in conditions OGG
The experimental groupDose, mg/kgLife duration in minutes (M±M)The growth time life, %Survival, %
Control-10.1±0.3-0
Cytoflavin100.036.1±0.6*+2570
Magnolia4.7029.2±0.4*+1890
Cytoflavin + lemongrass200+0.0530.5±1.4+2020
Cytoflavin + lemongrass200+2.35 47.3±1.2+36810
Cytoflavin + lemongrass200+4.4039.0±1.4+2860
Cytoflavin + lemongrass200+23.638.7±0.8+2830
Cytoflavin + lemongrass200+47.038.2±1.0+2790
Cytoflavin + lemongrass200+100.038.2±1.0+2790
Cytoflavin + lemongrass100+0.0538.8±0.7+2840
Cytoflavin + lemongrass100+2.3541.0±1.0*+30610
Cytoflavin + lemongrass100+4.7044.8±1.2*+34310
100+23.542.4±1.1*+32010
Cytoflavin + lemongrass100+47.040.8±1.6*+30310
Cytoflavin + lemongrass100+100.040.8±1.6*+30310
Cytoflavin + lemongrass50+0.0546.2±1.3*+35710
Cytoflavin + lemongrass50+2.3556.3±1.8*+45720
Cytoflavin + lemongrass50+4.7049.2±1.4*+38710
Cytoflavin + lemongrass50+23.552.1±1.1*+41520
Cytoflavin + lemongrass50+47.0 42.5±0.6*+32110
Cytoflavin + lemongrass50+100.042.5±0.6*+32110
Cytoflavin + lemongrass10+0.0537.3±1.2+2690
Cytoflavin + lemongrass10+2.3539.6±1.0*+29210
Cytoflavin + lemongrass10+4.7041.8±1.2*+31310
Cytoflavin + lemongrass10+23.542.8±1.5*+32410
Cytoflavin + lemongrass10+47.040.1±1.3*+29710
Cytoflavin + lemongrass10+100.040.1±1.3*+29710
Notes. Differences in all experimental groups, a significant relative to the control. *- p≤0.05 relative to cytoflavin

Table 4
The impact of the proposed integrated tools and components on the mortality of male rats in conditions of sub-chronic intoxication aniline
The experimental groupPalo animals/totalMortality, %
Control (water)0/80.0
And 500 mg/kg3/837.5
A+C, 100 mg/kg0/80.0
A+L 4.7 mg/kg0/80.0
A+C+L, 200+2.35 mg/kg0/80.0
A+C+L, 100+4.70 mg/kg0/80.0
A+C+L, 50+2.35 mg/kg0/80.0
THE+T+L, 10+23.5 mg/kg0/80.0

Table 5
The impact of the proposed integrated tools and components at the level of methemoglobin and hemovigilance in the peripheral blood in conditions of sub-chronic intoxication aniline
The experimental groupMetHb, %Hemovigilance, ug/l
Control (water)1.6±0.467.0±14.0
And 500 mg/kg19.4±1.6*738.0±41.0*
A+C, 100 mg/kg6.9±0.8*336.0±57.0*
A+L 4.7 mg/kg10.1±1.2*288.0±43.0*
A+C+L, 200+2.35 mg/kg5.9±1.1*159.0±15.0*
A+C+L, 100+4.70 mg/kg5.4±0.9*144.0±14.0*
A+C+L, 0+2.35 mg/kg 4.2±0.7*112.0±17.0*
A+C+L 10+23.5 mg/kg4.4±0.6*123.0±15.0*
Note - * - p≤0.05 compared to the group of intact animals;- p≤0.05 compared to animals not receiving treatment

Table 6
The impact of the proposed integrated tools and components on the indicators of the functional status of the liver and kidneys of rats in conditions of sub-chronic intoxication aniline
The experimental groupThe total bilirubin, µmol/lAlat, mmol/h·lAST, mmol/h·lAlkaline phosphatase, nmol/·lUrea, mmol/l
Control (water)10.60±0.400.23±0.060.38±0.10308±414.90±0.50
And g/s, 500 mg/kg24.50+1.80*4.64±0.45* 2.81±0.41*1789+102 *9.90±0.60*
A+C, 100 mg/kg13.40±0.90*1.39±0.26*1.16±0.51*689±58*6.40±0.20*
A+L, 4.70 mg/kg11.40±1.101.35±0.61 *1.28±0.33*885±92*5.90±0.70
A+C+L, 200+2.35 mg/kg12.90±1.201.49±0.22*1.24±0.31*656±54*6.30±0.40*
A+C+L, 100+4.70 mg/kg11.80±1.401.22±0.10*1.10±0.12*652±47*7.10±0.80*
A+C+L, 50+2.35 mg/kg11.20±1.701.79±0.18*1.42±0.27* 841±67*6.50±0.60*
A+C+L 10+23.5 mg/kg12.40±1.401.81±0.13*1.65±0.19*856±52*7.20±0.90*
Note - * - p≤0.05 compared to intact animals;- p≤0.05 compared to animals not receiving treatment

The treatment for the remote consequences of the poisoning metgemoglobinoobrazovatelami comprising dry extract of the fruits and seeds of schisandra (standardized to the total content of Lignano not less than 2.5%) and cytoflavin in the ratio of parts: 1:2-21.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to chemical - pharmaceutical industry, and deals with inhibitor of premature ovulation for application in in vitro fertilisation or in process of transferring embryo, which includes non-peptide compound, which has antagonistic with respect to gonadotropine-releasing hormone activity.

EFFECT: inhibitor of premature ovulation for application in in vitro fertilisation or in process of embryo transfer according to claimed invention is low-toxic, suitable to per oral introduction, and has excellent inhibiting action on premature ovulation in in vitro fertilisation or in process of embryo transfer.

4 cl, 23 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of veterinary. Medication includes diacetophenonyl selenide (DAPS-25), beta-carotene, vegetable oil and lycopene with the following component content, wt %: DAPS-25 - 0.18-0.24, beta-carotene- 0.1-0.2, lycopene - 0.1-0.2, vegetable oil - the remaining part.

EFFECT: medication is economical in manufacturing, application and storage.

6 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to obstetrics and gynecology and can be used for prevention of thromboembolic and inflammatory complications after Cesarean section operation in women from high risk group. For this purpose, intraoperationally 12 and 24 hours after delivery antibiotics are introduced. In addition, 12 hours after operative delivery under skin of anterior abdominal wall introduced are 40 mg of enoxaparin sodium. After that, 24 and 48 hours after introduction of the first dose also subcutaneously in area of anterior abdominal wall introduced are another 40 mg of enoxaparin sodium. Totally 3 injections during 3 days.

EFFECT: method makes it possible to reduce frequency of thromboembolic and inflammatory complications in women from high risk group after Cesarean section operation with minimal course of treatment.

3 ex, 6 tbl

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine and deals with optimised composition for RNA injection. Essence of invention includes application of mRNA and water injection buffer for preparation of solution for RNA injection, intended for transfer of mRNA and/or for its translation in host organism, injection solution includes Na+ with content 50 mM, Ca+ at least, 0.01 mM, content of K+ - 3 mM and optionally lactate.

EFFECT: increase of mRNA stability.

19 cl, 6 ex, 17 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of veterinary. Medication contains 2,4,6,8-tetramethyl-2,4,6,8-tetraasabicyclo- (3,3,0)- octadiselenon-3,7 as selenium source. As oil, medication contains peach oil with the following component ratio wt %: 2,4,6,8-tetramethyl-2,4,6,8-tetraasabicyclo- (3,3,0)- octadiselenon-3,7 - 20-40, peach oil - the remaining part.

EFFECT: medication possesses high immunostimulating activity, expressed anti-stress effect, is not toxic.

7 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to pulmonology, and can be used if diagnostic bronchoalveolar lavage required in patients suffering moderately severe and severe bronchial asthma. For this purpose, bronchofiberscopy is combined with single introduction and single aspiration of physiologic saline 8-10 ml heated to 37°C. Simultaneously, high-frequency jet pulmonary ventilation (HF JPV) at inspiration-expiration relation 1:2 and respiratory rate 160 per 1 min for 40-90 seconds is used.

EFFECT: technique provides faster and more voluminous fluid flow from alveoli to bronchial tubes due to prevented decrease in blood oxygenation while carrying out the procedure owing to the simultaneous use of HF JPV in a certain mode.

2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, namely to a method for producing pine essence by vapour distillation of raw ground at temperature and essence separation from the distillate. Strobiles of low juniper pre-grounded to 2-3 mm, or of Korean pine pre-grounded to 1.5-2,5 cm are kept for 2 hours at temperature 70°C in a hermetically sealed distillation bowl. Vapour distillation is carried out at pressure 0.09-0.12 MPa and temperature 100-110°C for 6 hours.

EFFECT: prepared pine essence exhibits higher content of biologically active substances and extends a raw material base for producing thereof.

2 ex, 6 tbl, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to development of agents showing bracing, tonic and rejuvenating action, based on herbal raw material which can be used for hydrotherapy for the purpose of prevention and treatment of various diseases. The yellow turpentine solution showing bracing, tonic and rejuvenating action contains: gum turpentine, castor oil, oleic acid, sodium hydroxide, a water-propyleneglycol herbal extract (ledum, burdock root, nettle, camomile, heather and sage herb, or fern greenery, birch leaves, oak bark, meadow clover and sage blossom clusters, and hop cones, or a camomile, lavender, rosemary, horsetail, sage and green coffee bean oil, demineralised water taken in the certain proportions.

EFFECT: agent provides better therapeutic action in prevention and treatment of specific diseases.

3 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to pharmacology and medicine. Fin order to obtain medicine, which has tissue-specific activity, animal organs are subjected to freezing not later than after 2 hours after raw material collection at temperature not lower than 40°C, kept at temperature minus 20-22°C during not less than two months. To milled frozen raw material 5% solution of acetic acid is added, bringing suspension temperature to 60-70°C and extraction of peptides into solution is carried out with constant mixing during not less than 2 hours. Supernatant fluid is siphoned and filtered through tissue, after which purified extract is directed to tangential micro-filtering. Obtained filtrate is directed to solid-phase extraction. Chromatography is carried out and on output from columns fractions of solutions are collected. Fractions, which contain peptide components, are united and directed to vacuum-evaporating plant, after which obtained target product is lyophilised.

EFFECT: method application makes it possible to obtain peptide complex with molecular weight of peptide components included in it from 75 to 5200 Da, which demonstrates pronounced tissue-specific activity.

8 cl, 14 tbl, 14 ex

FIELD: medicine.

SUBSTANCE: jejunal epithelium repair in old laboratory animal exposed to ionising radiation is ensured by intravenous transplantation of allogenic multipotent mesenchymal stromal cells recovered from placenta in amount 6×106 cell/kg 25-30 min after the exposure.

EFFECT: invention allows extending the range of products able to maintain repair tissue potential, namely antiapoptogenic action, higher cell turnover of crypt jujenal epithelium depressed by the ionising radiation exposure, with no therapeutic complications.

3 tbl

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine. Mixture consists of medicinal plants: inflorescences of pot marigold, peppermint leaves, Baikal skullcap root, black leaves and root of badan, shoots of shrubby cinquefoil, with the following component ratio, wt fr.: inflorescences of pot marigold 3; peppermint leaves 1; Baikal skullcap root 2; rhizome and black leaves of badan - 1+1; shoots of shrubby cinquefoil 2. Clinical treatment with claimed mixture has resulted in positive effect in case of alcoholic hepatitis in 150 patients.

EFFECT: creation of mixture for treatment and prevention of alcoholic hepatitis.

10 tbl

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine. Mixture consists of medicinal plants: inflorescences of pot marigold, peppermint leaves, Baikal skullcap root, black leaves and root of badan, shoots of shrubby cinquefoil, with the following component ratio, wt fr.: inflorescences of pot marigold 3; peppermint leaves 1; Baikal skullcap root 2; rhizome and black leaves of badan - 1+1; shoots of shrubby cinquefoil 2. Clinical treatment with claimed mixture has resulted in positive effect in case of alcoholic hepatitis in 150 patients.

EFFECT: creation of mixture for treatment and prevention of alcoholic hepatitis.

10 tbl

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine. Mixture consists of medicinal plants: inflorescences of pot marigold, peppermint leaves, Baikal skullcap root, black leaves and root of badan, shoots of shrubby cinquefoil, with the following component ratio, wt fr.: inflorescences of pot marigold 3; peppermint leaves 1; Baikal skullcap root 2; rhizome and black leaves of badan - 1+1; shoots of shrubby cinquefoil 2. Clinical treatment with claimed mixture has resulted in positive effect in case of alcoholic hepatitis in 150 patients.

EFFECT: creation of mixture for treatment and prevention of alcoholic hepatitis.

10 tbl

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine. Mixture consists of medicinal plants: inflorescences of pot marigold, peppermint leaves, Baikal skullcap root, black leaves and root of badan, shoots of shrubby cinquefoil, with the following component ratio, wt fr.: inflorescences of pot marigold 3; peppermint leaves 1; Baikal skullcap root 2; rhizome and black leaves of badan - 1+1; shoots of shrubby cinquefoil 2. Clinical treatment with claimed mixture has resulted in positive effect in case of alcoholic hepatitis in 150 patients.

EFFECT: creation of mixture for treatment and prevention of alcoholic hepatitis.

10 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, namely to creation of composition of dense extract of conifer needles for capsulation. Composition of dense extract of conifer needles contains the following ingredients: dense extract of conifer needles, emulsifier, a-tocopherol (vitamin E), retinol (vitamin A), naphthoquinones (vitamin K), essential fatty acids (vitamin F), vegetable oil. Microelements can be included additionally.

EFFECT: composition improves state of mucous membranes and enhances protective properties of organism.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of pharmacology, medicine and food industry and deals with medicine for reduction of visceral fatty tissue accumulation, which contains compounds of formula or extract of plant Liliaceae, which includes these compounds, application of said compounds or extracts for inhibition of visceral fatty tissue accumulation as well as product on their basis.

EFFECT: invention insures efficient reduction of visceral fatty tissue accumulation.

19 cl, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of pharmacology, medicine and food industry and deals with medicine for reduction of visceral fatty tissue accumulation, which contains compounds of formula or extract of plant Liliaceae, which includes these compounds, application of said compounds or extracts for inhibition of visceral fatty tissue accumulation as well as product on their basis.

EFFECT: invention insures efficient reduction of visceral fatty tissue accumulation.

19 cl, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to veterinary and can be used for external application in treatment of dogs, cats, fur-bearing animals and other small pets with disease of bacterial-mycotic-mite etiology. Cream for treatment of skin disease of small pets, contains acaricidic, anti-mycotic-antimicrobial substances, wt %: 20% Roksacin 1.8-2.1; 1% Aversect-2 7.8-8.1; child's cream on grease base - the remaining part.

EFFECT: invention insures increasing of efficiency and reduction of treatment terms.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to urology and rehabilitation medicine, and deals with prevention and complex treatment of urolithiasis after distant lithotripsy. For this purpose after distant-shock-wave lithotripsy carried out is litholytic, antibacterial, antispasmodic, analgesic therapy with administration of a diet. Additionally introduced is infusion of medicinal plants, which contains bearberry leaves, leaves of Indian kidney tea, knotweed grass, dill fruits, burdock root, nettle leaves, rowan fruits, taken in equal component ratio. Infusion is introduced in dose 100 ml 3 times for day 30 min before meal for 10 days at the background of carried out basic therapy and for 4 weeks after its withdrawal, basic therapy.

EFFECT: method ensures efficient prevention and treatment due to complex impact on all links of urolithiasis pathogenesis.

3 cl, 1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to urology and rehabilitation medicine, and deals with prevention and complex treatment of urolithiasis after distant lithotripsy. For this purpose after distant-shock-wave lithotripsy carried out is litholytic, antibacterial, antispasmodic, analgesic therapy with administration of a diet. Additionally introduced is infusion of medicinal plants, which contains bearberry leaves, leaves of Indian kidney tea, knotweed grass, dill fruits, burdock root, nettle leaves, rowan fruits, taken in equal component ratio. Infusion is introduced in dose 100 ml 3 times for day 30 min before meal for 10 days at the background of carried out basic therapy and for 4 weeks after its withdrawal, basic therapy.

EFFECT: method ensures efficient prevention and treatment due to complex impact on all links of urolithiasis pathogenesis.

3 cl, 1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, namely to creation of composition of dense extract of conifer needles for capsulation. Composition of dense extract of conifer needles contains the following ingredients: dense extract of conifer needles, emulsifier, a-tocopherol (vitamin E), retinol (vitamin A), naphthoquinones (vitamin K), essential fatty acids (vitamin F), vegetable oil. Microelements can be included additionally.

EFFECT: composition improves state of mucous membranes and enhances protective properties of organism.

2 ex

Up!